Minoxidil promotes hair regrowth in androgenetic alopecia
4 events · 1 assessment · 1 contribution · 1 decision
Assessed Verified
verdict confidence 0.88 · credence 0.97
Minoxidil is one of the best-established treatments for androgenetic alopecia (pattern hair loss). Randomized placebo-controlled trials in both men and women, spanning several decades, consistently show that topical minoxidil increases non-vellus hair count relative to placebo, and pooled analyses, including a Cochrane systematic review of female pattern hair loss, confirm the effect. On this evidence the FDA approved topical minoxidil for the indication, first at 2% and later at 5%. The effect has well-known limits that do not undermine the claim itself: regrowth is moderate rather than complete, a substantial fraction of patients respond weakly or not at all, results are typically better at the vertex than the frontal hairline, and gains reverse within months if treatment stops. The live questions in the current literature concern optimization, such as low-dose oral minoxidil and combinations with 5-alpha-reductase inhibitors, not whether minoxidil promotes regrowth at all.
Claim proposal accepted
The submission proposes a new claim: whether Minoxidil is effective for hair growth in balding individuals. This is a genuine, well-established topic of discourse (Minoxidil's efficacy for androgenetic alopecia is widely discussed in medical and consumer literature, with real variation in outcomes and debate over effect size, responder rates, and populations for whom it works), so it satisfies the No-Origination requirement: this is not a proposition of the contributor's own coinage but one that appears throughout the discourse. It also meets the §2 claim bar: it is a single, reusable, disputable proposition capable of anchoring an ongoing debate and accumulating evidence and argument, rather than a fragment, question-as-rhetoric, or uncontested definition. The proposed canonical form ("Does Monoxidil help with hair growth?") is phrased as a question and misspells the drug name, but this is fixable wording, not wording so loaded that no neutral statement can be recovered. The Matcher and Steward are responsible for refining this into a proper affirmative canonical form (e.g., "Minoxidil promotes hair growth in people experiencing balding") and correcting the spelling; per intake policy, imperfect-but-fixable wording is acceptable at this stage. The accompanying content ("There seems to be some debate as to whether Minoxidil really helps...") is a sincere, on-topic assertion that a live debate exists on this question. It need not be convincing or evidenced at the intake stage — assessment and evidence-gathering are the Steward's job after admission — only sincere and on-topic, which it is. The contributor has no prior history (0 contributions), standard trust, good standing, no bad-faith flags. Nothing here suggests spam, vandalism, or coordinated abuse; this reads as a good-faith, if terse, attempt to add a real topic to the graph.
NORCI§2§3
Claim entered the graph
Claim proposal submitted
There seems to be some debate as to whether Minoxidil really helps with hair growth on balding people.